Michelle Wilson

2.0k total citations
62 papers, 879 citations indexed

About

Michelle Wilson is a scholar working on Reproductive Medicine, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Michelle Wilson has authored 62 papers receiving a total of 879 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Reproductive Medicine, 23 papers in Oncology and 15 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Michelle Wilson's work include Ovarian cancer diagnosis and treatment (25 papers), PARP inhibition in cancer therapy (14 papers) and BRCA gene mutations in cancer (5 papers). Michelle Wilson is often cited by papers focused on Ovarian cancer diagnosis and treatment (25 papers), PARP inhibition in cancer therapy (14 papers) and BRCA gene mutations in cancer (5 papers). Michelle Wilson collaborates with scholars based in Canada, New Zealand and United States. Michelle Wilson's co-authors include Amit M. Oza, Katherine Karakasis, Michael Friedländer, Helen Mackay, Michael Findlay, Michael B. Jameson, Bruce C. Baguley, Clare Wall, Lisa Wang and Stéphanie Lheureux and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Michelle Wilson

60 papers receiving 854 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michelle Wilson Canada 17 210 173 159 126 114 62 879
Charles Weissman Israel 21 251 1.2× 178 1.0× 326 2.1× 186 1.5× 286 2.5× 80 1.5k
Louise F. Wilson Australia 22 422 2.0× 168 1.0× 85 0.5× 246 2.0× 87 0.8× 53 1.2k
Leila Allahqoli Iran 18 338 1.6× 243 1.4× 76 0.5× 119 0.9× 69 0.6× 119 1.2k
C Hermon United Kingdom 20 413 2.0× 270 1.6× 176 1.1× 344 2.7× 72 0.6× 29 1.6k
Mara M. Epstein United States 17 272 1.3× 36 0.2× 129 0.8× 135 1.1× 181 1.6× 61 822
Erin O’Leary Canada 14 121 0.6× 47 0.3× 206 1.3× 155 1.2× 216 1.9× 27 860
Mark W. Donoghoe Australia 16 123 0.6× 80 0.5× 180 1.1× 113 0.9× 115 1.0× 53 1.1k
Marike Boezen Netherlands 17 246 1.2× 184 1.1× 185 1.2× 83 0.7× 237 2.1× 29 1.2k
Zhezhou Huang China 14 194 0.9× 38 0.2× 163 1.0× 87 0.7× 63 0.6× 35 748
J R Daling United States 17 290 1.4× 85 0.5× 111 0.7× 250 2.0× 78 0.7× 30 1.1k

Countries citing papers authored by Michelle Wilson

Since Specialization
Citations

This map shows the geographic impact of Michelle Wilson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Wilson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Wilson more than expected).

Fields of papers citing papers by Michelle Wilson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Wilson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Wilson. The network helps show where Michelle Wilson may publish in the future.

Co-authorship network of co-authors of Michelle Wilson

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Wilson. A scholar is included among the top collaborators of Michelle Wilson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Wilson. Michelle Wilson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Howard, Jane, Cristina Casalou, Brendan S. Kelly, et al.. (2024). Proteomic and metabolomic profiles of plasma-derived Extracellular Vesicles differentiate melanoma patients from healthy controls. Translational Oncology. 50. 102152–102152. 6 indexed citations
2.
3.
Lheureux, Stéphanie, Taymaa May, Michelle Wilson, et al.. (2024). Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.. Journal of Clinical Oncology. 42(16_suppl). 5506–5506. 1 indexed citations
4.
O’Malley, David M., Iain A. McNeish, Thomas J. Herzog, et al.. (2024). 49MO Updated progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) treated with rucaparib (RUC) in ATHENA-MONO. ESMO Open. 9. 103556–103556. 1 indexed citations
5.
Friedländer, Michael, Linda Mileshkin, Janine Lombard, et al.. (2023). Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial. British Journal of Cancer. 129(5). 797–810. 9 indexed citations
6.
Oaknin, Ana, Rebecca Kristeleit, Myong Cheol Lim, et al.. (2022). 2022-LBA-325-ESGO Patients with newly diagnosed ovarian cancer treated with maintenance rucaparib: exploratory biomarker analysis from the phase 3 ATHENA-MONO study (GOG-3020/ENGOT-ov45; NCT03522246). International Journal of Gynecological Cancer. 32. A472–A472. 1 indexed citations
7.
Lee, Yeh Chen, Hao‐Wen Sim, Tanya Chawla, et al.. (2022). Interobserver and intraobserver variability of RECIST assessment in ovarian cancer. International Journal of Gynecological Cancer. 32(5). 656–661. 7 indexed citations
8.
Wilson, Michelle, et al.. (2019). Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology. Cancer Drug Resistance. 2(3). 608–617. 15 indexed citations
9.
Mercieca‐Bebber, Rebecca, Claudia Rutherford, Lucy Busija, et al.. (2018). Trials with proxy-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR). Quality of Life Research. 28(4). 955–962. 3 indexed citations
10.
Mercieca‐Bebber, Rebecca, Jessica Roydhouse, Lucy Busija, et al.. (2018). Trials with patient-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR). Quality of Life Research. 27(10). 2581–2591. 31 indexed citations
11.
Wilson, Michelle, et al.. (2017). Mortality within 30 days of systemic anticancer therapy at a tertiary cancer centre: assessing the safety and quality of clinical care.. PubMed. 130(1460). 63–72. 4 indexed citations
12.
Wilson, Michelle, Michael Friedländer, Florence Joly, & Amit M. Oza. (2017). A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve. The Oncologist. 23(2). 203–213. 21 indexed citations
13.
Dhani, Neesha C., Hal W. Hirte, Marcus O. Butler, et al.. (2016). Phase II study of cabozantinib in recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago and California Phase II Consortia.. Journal of Clinical Oncology. 34(15_suppl). 5586–5586. 1 indexed citations
14.
15.
Wilson, Michelle, Katherine Karakasis, & Amit M. Oza. (2014). Outcomes and endpoints in trials of cancer treatment: the past, present, and future. The Lancet Oncology. 16(1). e32–e42. 151 indexed citations
16.
Rosario, Roseanne, Michelle Wilson, Kathryn Payne, et al.. (2013). Adult granulosa cell tumours (GCT): Clinicopathological outcomes including FOXL2 mutational status and expression. Gynecologic Oncology. 131(2). 325–329. 27 indexed citations
17.
Dancause, Kelsey N., Miguel G. Vilar, Michelle Wilson, et al.. (2013). Behavioral risk factors for obesity during health transition in Vanuatu, South Pacific. Obesity. 21(1). E98–E104. 32 indexed citations
18.
Dancause, Kelsey N., Miguel G. Vilar, Chim W. Chan, et al.. (2011). Patterns of childhood and adolescent overweight and obesity during health transition in Vanuatu. Public Health Nutrition. 15(1). 158–166. 20 indexed citations
19.
Hicks, Mark, et al.. (2005). The case for a standardised protocol that includes hormone resuscitation for the management of the cadaveric multi-organ donor. Critical Care and Resuscitation. 7(1). 43–50. 7 indexed citations
20.
Wilson, Michelle, et al.. (1994). A Case Study of Race Differences Among Late Abortion Patients. Women & Health. 21(4). 43–56. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charles Weissman Breakdown of academic impact, for papers by Louise F. Wilson Breakdown of academic impact, for papers by Leila Allahqoli Breakdown of academic impact, for papers by C Hermon Breakdown of academic impact, for papers by Mara M. Epstein Breakdown of academic impact, for papers by Erin O’Leary Breakdown of academic impact, for papers by Mark W. Donoghoe Breakdown of academic impact, for papers by Marike Boezen Breakdown of academic impact, for papers by Zhezhou Huang Breakdown of academic impact, for papers by J R Daling
Rankless by CCL
2026